Accueil / Tag Archives: New-York (page 273)

Tag Archives: New-York

Pfizer Completes Acquisition Of Nimenrix And Mencevax From GlaxoSmithKline

Thursday, October 1st 2015 at 12:00pm UTC NEW YORK–(BUSINESS WIRE)– Pfizer Inc. (NYSE:PFE) today announced that it has completed the acquisition of GlaxoSmithKline’s quadrivalent meningococcal ACWY vaccines Nimenrix and Mencevax. “The addition of Nimenrix and Mencevax helps us to fulfill our vision to protect lives with innovative vaccines to fight …

Plus »

Jounce Therapeutics Announces Presentation at the Leerink Partners Immuno-Oncology Roundtable

Thursday, October 1st 2015 at 1:54pm UTC CAMBRIDGE, Mass.–(BUSINESS WIRE)– Jounce Therapeutics, Inc., a company focused on the discovery and development of novel cancer immunotherapies coupled to patient selection strategies, today announced that Richard Murray, Ph.D., chief executive officer, will present a company overview at the Leerink Partners Immuno-Oncology Roundtable …

Plus »

Stéphane Bessette is appointed Executive Vice President, Human Resources of Ipsen

Thursday, October 1st 2015 at 6:15am UTC PARIS–(BUSINESS WIRE)– Regulatory News: Ipsen (Euronext: IPN;ADR: IPSEY) today announced the appointment of Stéphane Bessette as Executive Vice President, Human Resources of the Ipsen Group, as of today. He will report to Christel Bories, Deputy Chief Executive Officer of Ipsen, and will sit …

Plus »

Stéphane Bessette est nommé Vice-Président Exécutif en charge des Ressources Humaines d’Ipsen

Thursday, October 1st 2015 at 6:15am UTC PARIS–(BUSINESS WIRE)– Regulatory News: Ipsen (Euronext : IPN ; ADR : IPSEY) a annoncé aujourd’hui la nomination de Stéphane Bessette en qualité de Vice-Président Exécutif en charge des Ressources Humaines du Groupe Ipsen, à compter de ce jour. Il rapportera à Christel Bories, Directeur Général …

Plus »

Ovid Therapeutics Appoints Dr. Karen Bernstein to its Board of Directors

Wednesday, September 30th 2015 at 8:15pm UTC NEW YORK–(BUSINESS WIRE)– Ovid Therapeutics Inc. (Ovid), a privately held biopharmaceutical company focused on developing therapies for rare and orphan diseases of the brain, announced today the appointment of Karen Bernstein, Ph.D., to the Company’s Board of Directors. Dr. Bernstein is widely known …

Plus »

SERMO Partners with Global Genes to Battle Rare Diseases

Wednesday, September 30th 2015 at 6:49pm UTC New SERMOheroes Program Helps Patients with Rare Diseases Benefit from Medical Crowdsourcing NEW YORK–(BUSINESS WIRE)– SERMO, the leading global social network for physicians, and Global Genes™, a leading rare disease patient advocacy organization, announced at the 4th annual Rare Patient Advocacy Summit this weekend …

Plus »

Pfizer Partners with Breast Cancer Leaders to Chronicle the Lives of Women with Metastatic Breast Cancer through the Lenses of Prominent Photographers

Wednesday, September 30th 2015 at 9:00pm UTC Next chapter of the “Breast Cancer: A Story Half Told” initiative encourages all to share photos and messages of hope using the hashtag #StoryHalfTold NEW YORK–(BUSINESS WIRE)– Pfizer Inc., in partnership with five leading breast cancer advocacy organizations, today announced the next chapter …

Plus »

Tyme Technologies, Inc. Submits Investigational New Drug Application for Oncology Drug Candidate SM-88

Wednesday, September 30th 2015 at 12:30pm UTC NEW YORK–(BUSINESS WIRE)– Tyme Technologies, Inc. (Tyme, Inc.) (OTC QB:TYMI), a research and development company focused on developing first-in-class oncology drug candidates, has submitted a Phase 2 Investigational New Drug (IND) Application to the U.S. Food and Drug Administration (FDA) for SM-88, a drug …

Plus »

Baxter Appoints Munib Islam to Board; Announces Agreement with Third Point

Wednesday, September 30th 2015 at 1:00pm UTC DEERFIELD, Ill. & NEW YORK–(BUSINESS WIRE)– Baxter International Inc. (NYSE: BAX) today announced it has reached an agreement with Third Point LLC to appoint Munib Islam to its Board of Directors immediately and add another, mutually agreed upon independent director in the near-term. …

Plus »
>
Macbook Pro
* Intel Core i7 (3.8GHz, 6MB cache)
* Retina Display (2880 x 1880 px)
* NVIDIA GeForce GT 750M (Iris)
* 802.11ac Wi-Fi and Bluetooth 4.0
* Thunderbolt 2 (up to 20Gb/s)
* Faster All-Flash Storage (X1)
* Long Lasting Battery (9 hours)
BIENVENUE CHEZ BIOTECH FINANCES
Vous appréciez nos informations ?
Recevez nos alertes, nos dernières actualités, suivez-nous, enregistrez-vous gratuitement, rejoignez notre communauté. Merci à vous !
ARE YOU READY? GET IT NOW!
Increase more than 500% of Email Subscribers!
Your Information will never be shared with any third party.
DÉCOUVREZ LA SOLUTION STRATA !
PGlmcmFtZSB3aWR0aD0iMTAwJSIgaGVpZ2h0PSIxMDAlIiBzcmM9Imh0dHBzOi8vd3d3LmJpb3RlY2gtZmluYW5jZXMuY29tL3dwLWNvbnRlbnQvdXBsb2Fkcy8yMDE1LzA3L1NhdHJhLTIubXA0IiBmcmFtZWJvcmRlcj0iMCIgYWxsb3dmdWxsc2NyZWVuPjwvaWZyYW1lPg==
Retrouvez nous sur http://stratahealth.com/fr/
Un ensemble de solutions performantes
pour assurer le continuum de vos données.
Biotech Finances
SUIVEZ-NOUS, ENREGISTREZ-VOUS !
PGlmcmFtZSB3aWR0aD0iMTAwJSIgaGVpZ2h0PSIxMDAlIiBzcmM9Imh0dHA6Ly93d3cueW91dHViZS5jb20vZW1iZWQvajhsU2NITzJtTTAiIGZyYW1lYm9yZGVyPSIwIiBhbGxvd2Z1bGxzY3JlZW4+PC9pZnJhbWU+
All rights reserved © Company Name, 2014
Concours Genopole Young Biotech Award
* 100 000 € pour la meilleure Biotech
* Réservé aux biotechs hors santé
* 6 mois d'hébergement gratuit
* Un accompagnement personnalisé
* Etude de marché offerte
* Expertise du projet par EY
* Et nombre d'autres avantages...
S'inscrire au 15H BIOTECH EXPRESS
Chaque jour à 15H recevez gratuitement les news des biotechs, des medtechs,et des fonds spécialisés. Levées ; partenariats ; nominations ; fusacq ; closing ; milestone...
2019 (C) All rights reserved.

En cochant cette case, j’accepte la Politique de confidentialité de ce site et de recevoir des informations de notre part.

S'inscrire au 15H BIOTECH EXPRESS
Chaque jour à 15H recevez gratuitement les news des biotechs, des medtechs,et des fonds spécialisés. Levées ; partenariats ; nominations ; fusacq ; closing ; milestone...
2019 (C) All rights reserved.

En cochant cette case, j’accepte la Politique de confidentialité de ce site et de recevoir des informations de notre part.